Home Compare NOVN.SW vs RMD
Stock Comparison · Structural lead, mixed market

Novartis vs ResMed: Which Stock Looks Stronger in 2026?

The structural profiles are close, with ResMed carrying a narrow edge on valuation. Novartis still leads on profitability and stability, which keeps the comparison from looking entirely one-sided. In the market, Novartis carries the stronger setup — intact trend against ResMed's broken trend. That leaves a split case: the structural lead stays with ResMed, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (NOVN.SW: STOXX 600, RMD: S&P 500).

Updated 2026-07-05

Most of the lead runs through valuation, while growth helps make the separation broader.

Trajectory Similarity
0.67
Moderately similar
Peer-set rank: #6
within Novartis AG's functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

The pair shares a valid long-term profile match, but the trajectories are not especially close.

The strongest overlap appears in revenue stability and capital structure.

Similarity drivers
revenue stabilitycapital structure
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
NOVN.SW
Novartis AG
56
Peer-Score
Signal qualityHigh
Peer basis: STOXX 600
vs
RMD
ResMed Inc.
60
Peer-Score
Signal qualitylow
Peer basis: S&P 500

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: NOVN.SW vs RMD Profitability 67 56 Stability 79 54 Valuation 55 85 Growth 17 35 NOVN.SW RMD
Gap Ranking
#1 Valuation +30
#2 Stability +25
#3 Growth +18
#4 Profitability +11
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for NOVN.SW and RMD Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer NOVN.SWRMD Relative valuation Structural strength

The structural gap is limited here, but current pricing still leans against Novartis AG.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Entry today — historical context

Where NOVN.SW and RMD each sit in their own 5-year price and valuation history.

BASED ON 5-YEAR HISTORY NOVN.SW Elevated · above norm 0th 50th 100th 65 pct gap RMD Neutral · below norm 0th 50th 100th 99th 34th
Today RMD sits in the lower-middle of its own 5-year history (34th percentile), while NOVN.SW sits higher in its own history (99th). Within each stock's own 5-year context, RMD is at a historically more favourable entry position than NOVN.SW. This reflects entry timing, not which company is structurally stronger — peer-relative analysis is a separate question addressed above.

Describes historical entry positioning only. Descriptive — not investment advice.

Relative Position vs Comparable Companies
Valuation
Both rank well on valuation, but ResMed Inc. still holds a clear edge.
Stability
On stability, the edge still sits with Novartis AG, even though both profiles look solid.
Valuation — Dominant Gap
NOVN.SW
55
RMD
85
Gap+30in favour of RMD

The multiple-based pricing edge comes from a trailing P/E that is 2.4 turns lower.

What keeps the gap from being one-sided

There is still a strong counterforce in stability, so the lead stays clear without becoming a sweep.

What this means for the comparison

Valuation is the clearest driver of the lead, with stability adding further support — though profitability still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the NOVN.SW vs RMD comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how NOVN.SW and RMD each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.